US FTC seeks additional info on Pfizer’s proposed takeover of Seagen
2/2
FILE PHOTO: The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File Photo/File Photo
2/2
AMGN
-0.10%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
PFE
+0.72%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
HZNP
+0.23%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
(Reuters) -The US Federal Trade Commission (FTC) has sought additional information and documentary material related to Pfizer (NYSE:PFE)’s proposed acquisition of Seagen Inc, Seagen said on Friday.
The antitrust agency sent the requests separately to both the companies, a regulatory filing said.
Pfizer struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies, to counter the fall in COVID-related sales and generic competition for some top-selling drugs.
The recent scrutiny by the antitrust agency to block Amgen (NASDAQ:AMGN)’s $27.8 billion deal to buy Horizon Therapeutics (NASDAQ:HZNP) has made investors jittery around the Pfizer-Seagen deal as well.
Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024, it said in the filing.
